Incidence, Frequency, and Clinical Characteristics of Type 3 Myocardial Infarction in Clinical Practice - 27/09/17
Abstract |
Objectives |
Cardiac death in a patient with symptoms and electrocardiographic changes indicative of myocardial ischemia but without available measurements of cardiac biomarkers is designated a type 3 myocardial infarction. We wanted to investigate the incidence, the frequency, and the characteristics of patients diagnosed as type 3 myocardial infarction.
Methods |
The occurrence of deaths in a well-defined geographic region was retrieved from the Danish Civil Registration System during a 1-year period from 2010 to 2011. Complementary data concerning causes of deaths were obtained from the Danish Register of Causes of Death, and ambulance and hospital patient files. Adjudication of the diagnosis was done by 2 local experts and one external senior cardiologist.
Results |
A total of 2766 of the 246,723 adult residents in the region had died. A type 3 myocardial infarction was diagnosed in 18 individuals, corresponding to an annual incidence of 7.3/100,000 person-years. During the same 1-year period, 488 patients had other types of myocardial infarction implying a 3.6% frequency of type 3 myocardial infarction (18 of 506) among all myocardial infarctions.
Conclusion |
Type 3 myocardial infarction is a rare observation in clinical practice with an annual incidence below 10/100,000 person-years and a frequency of 3%-4% among all types of myocardial infarction. If autopsy data are included, the number of type 3 myocardial infarctions will increase.
El texto completo de este artículo está disponible en PDF.Keywords : Mortality/survival, Quality and outcomes, Resource utilization, Syncope
Esquema
| Funding: None. |
|
| Conflict of Interest: None. |
|
| Authorship: All authors had access to the data and a role in writing the manuscript. |
Vol 130 - N° 7
P. 862.e9-862.e14 - juillet 2017 Regresar al número
Artículo precedente
- Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies
- David A. Hanley, Michael R. McClung, K. Shawn Davison, Larry Dian, Steve T. Harris, Paul D. Miller, E. Michael Lewiecki, David L. Kendler, Writing Group for the Western Osteoporosis Alliance
- Time to Clinically Relevant Fracture Risk Scores in Postmenopausal Women
- Margaret L. Gourlay, Robert A. Overman, Jason P. Fine, Carolyn J. Crandall, John Robbins, John T. Schousboe, Kristine E. Ensrud, Erin S. LeBlanc, Margery L. Gass, Karen C. Johnson, Catherine R. Womack, Andrea Z. LaCroix, Women's Health Initiative Investigators
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?